≡

Multiplex Assay Kit for Granzyme B (GZMB) ,etc. by FLIA (Flow Luminescence Immunoassay)

GZM-B; HLP; CTLA1; CCPI; CGL1; CSP-B; CSPB; CTSGL1; SECT; Granzyme 2; Cytotoxic T-Lymphocyte-Associated Serine Esterase 1; Fragmentin 2; Cytotoxic Serine Protease B

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Granzyme B (GZMB) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Granzyme B (GZMB) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Granzyme B (GZMB) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Granzyme B (GZMB) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 97-104 101
EDTA plasma(n=5) 92-99 96
heparin plasma(n=5) 90-97 93
sodium citrate plasma(n=5) 81-91 87

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Granzyme B (GZMB) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Granzyme B (GZMB) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Granzyme B (GZMB) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 80-105% 90-98% 96-104% 83-98%
EDTA plasma(n=5) 78-101% 82-96% 92-105% 78-94%
heparin plasma(n=5) 80-98% 98-105% 92-101% 96-105%
sodium citrate plasma(n=5) 87-97% 82-104% 79-95% 94-102%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:GZMB) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
International Journal of Cancer Effective immunotherapy of rat glioblastoma with prolonged intratumoral delivery of exogenous heat shock protein Hsp70 Pubmed:24691976
Biol Pharm Bull. Z-100, an Immunomodulatory Extract of Mycobacterium tuberculosis Strain Aoyama B, Prevents Spontaneous Lymphatic Metastasis of B16-BL6 Melanoma Pubmed:24818259
Journal of Dermatological Science Relationships among plasma granzyme B level, pruritus and dermatitis in patients with atopicdermatitis. pubmed:27686401
Oncotarget Tumor-derived granzyme B-expressing neutrophils acquire antitumor potential after lipid A treatment Pubmed:29983866
Theranostics A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors Pubmed: 31695790
Am J Transl Res Combined treatment with epigenetic agents enhances anti-tumor activity of T cells by upregulating the ACRBP expression in hepatocellular carcinoma 34377237
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPA600Hu01 Recombinant Granzyme B (GZMB) Positive Control; Immunogen; SDS-PAGE; WB.
PAA600Hu01 Polyclonal Antibody to Granzyme B (GZMB) WB; IHC
MAA600Hu22 Monoclonal Antibody to Granzyme B (GZMB) WB
MAA600Hu21 Monoclonal Antibody to Granzyme B (GZMB) WB
SEA600Hu ELISA Kit for Granzyme B (GZMB) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA600Hu Multiplex Assay Kit for Granzyme B (GZMB) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.